- COMMENT
Digital technologies for medicines: shaping a framework for success
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 19, 573-574 (2020)
doi: https://doi.org/10.1038/d41573-020-00080-6
Acknowledgements
The authors acknowledge the contributions to this article of the following experts: C. Vincenzi (EMA); S. Corriol-Rohou (AstraZeneca); F. Albissola (Sanofi); S. Almeida (Medicines for Europe); M. vonFritschen (Eucope); A. Schepers (GSK), F. Ruediger (Grunenthal) and T. Chesworth (AstraZeneca).
Disclaimer
The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the organizations they are affiliated with, the European Medicines Agency or one of its committees or working parties.
Competing Interests
T.M. is employed by F. Hoffmann-La Roche and owns shares. S.A. is employed by Novartis Pharma and owns shares. J.D. is employed by Alexion and owns shares.